Helicobacter pylori Antibiotic Resistance in Egypt: A Single-Center Study
Mohamed Metwally,Raghda Ragab,Hasnaa S Abdel Hamid,Nashwa Emara,Hany Elkholy
DOI: https://doi.org/10.2147/IDR.S386082
2022-10-12
Infection and Drug Resistance
Abstract:Mohamed Metwally, 1 Raghda Ragab, 1 Hasnaa S Abdel Hamid, 2 Nashwa Emara, 3 Hany Elkholy 1 1 Department of Hepatology, Gastroenterology and Infectious Diseases, Faculty of Medicine, Benha University, Benha, Qualubia, Egypt; 2 Department of Microbiology and Immunology, Faculty of Medicine, Benha University, Benha, Qualubia, Egypt; 3 Department of Histopathology, Faculty of Medicine, Benha University, Benha, Qualubia, Egypt Correspondence: Mohamed Metwally, Hepatology, Gastroenterology, and Infectious Diseases Department, Benha University Hospital, PO Pox: 31518, Benha, Qualubia, Egypt, Tel +02 0106-4917959, Fax +02 013-3228631, Email Purpose: Helicobacter pylori ( H. pylori ) is the most common human bacterial infection worldwide, infecting approximately half of the world's population. Although antibiotic use is indicated for H. pylori eradication, the recommended type of antibiotic varies from country to country according to the H. pylori resistance pattern; developing countries, such as Egypt, may have different patterns than developed countries. We evaluated the antibiotic resistance of H. pylori in Egypt. Methods: This cross-sectional study included 134 adult patients with upper gastrointestinal (GI) complaints. Patients with a history of PPI during the last 2 weeks or antibiotics during the last 4 weeks before endoscopy were excluded. Upper GI endoscopies were performed and biopsies were collected for histopathology and H. pylori culture. Demographic, clinical, and endoscopic data were also collected. Antimicrobial susceptibility testing for H. pylori was performed for nine therapeutically relevant antibiotics using the Kirby–Bauerdisc diffusion method. Results: The H. pylori antibiotic resistance rates were as follows: moxifloxacin, 10%; doxycycline, 15%; levofloxacin, 20%; clarithromycin, 40%; azithromycin, 40%; erythromycin, 65%; rifampicin, 90%; amoxicillin, 95%; and metronidazole, 100%. Dual resistance rates were 40% for amoxicillin/clarithromycin, 40% for metronidazole/clarithromycin, and 95% for amoxicillin/metronidazole. Conclusion: In Egyptian patients, H. pylori had > 90% resistance to metronidazole and amoxicillin; modest resistance to erythromycin, azithromycin, and clarithromycin; and low resistance to moxifloxacin, and levofloxacin (≤ 20%). Dual resistance was high for amoxicillin/clarithromycin and amoxicillin/metronidazole, which prefers using quinolones rather than clarithromycin or metronidazole for first-line treatment of H. pylori in Egypt. Keywords: Helicobacter pylori antibiotic resistance, H. pylori culture, H. pylori treatment Helicobacter pylori ( H. pylori ) is the most widespread human pathogen, infecting about 50% of the global population. 1 H . pylori is a major cause of peptic ulcers and a risk factor for gastric cancer and mucosa-associated lymphoid tissue (MALT) lymphomas. 2 H. pylori may also be associated with extra-intestinal diseases, including immune thrombocytopenic purpura, refractory iron deficiency anemia, and vitamin B12 deficiency. 3 The prevalence of H. pylori infection varies globally according to socioeconomic factors and levels of hygiene. In Egypt, the prevalence of H. pylori infection is high; the prevalence of H. pylori is up to 70% in dyspeptic patients. 4 H. pylori is typically treated with a combination of 2–3 antibiotics and a proton pump inhibitor (PPI), taken concomitantly or sequentially, for periods ranging from 10 to 14 days. In clinical practice, the initial course of eradication therapy referred to as "first-line" therapy is usually the most successful. 5 The success of eradication therapy largely depends on the rapid emergence of antibiotic-resistant strains of H. pylori . Antibiotic resistance is a constantly evolving process and the prevalence of H. pylori antibiotic resistance varies significantly from country to country and even between regions within the same country. 6 The progressive loss of standard eradication therapy efficacy makes treating H. pylori more challenging than ever. Endoscopic guided antibiotic susceptibility testing may guide treatment after failure of second-line therapies. 7 The last consensus for H. pylori management in Egypt recommended the same first- and second-line therapies as the international guidelines 8 ; however, many studies recommend the identification of H. pylori antibiotic resistance. We aimed to evaluate the susceptibility -Abstract Truncated-
pharmacology & pharmacy,infectious diseases